As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company's making these strides have incredible results to show for it.

Shares of the biopharmaceutical company are on pace for their best day in more than six years.

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Exec...

Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakafi.

Incyte (INCY) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.60 per share a year ago.

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress.

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.